News
-
25 January 2016
Immunocore’s IMCgp100 Granted Orphan Drug Designation by US FDA for the Treatment of Uveal Melanoma -
20 January 2016
Immunocore Starts Clinical Trial with IMCgp100 in Combination with MedImmune Immunotherapies Durvalumab and Tremelimumab -
6 January 2016
Immunocore and GlaxoSmithKline Select First ImmTAC Clinical Candidate in Discovery Collaboration -
17 December 2015
Immunocore expands its senior management team and opens US Office -
3 December 2015
Immunocore wins Biotech of the Year at the SCRIP Awards 2015 -
9 September 2015
Immunocore’s IMCgp100 Accepted for Adaptive Pathway Pilot Programme -
7 September 2015
Immunocore Ranked No 1 South East Company in the Annual Sunday Times Hiscox Tech Track 100 -
6 August 2015
The Royal Society publishes a video case study on Immunocore -
29 July 2015
Immunocore announces Fidelity’s Participation in $320M Financing -
16 July 2015
Immunocore secures $320 million (£205 million) in Europe’s Largest Private Life Sciences Financing